a cancer to and significant Thanks sense drive autoimmune our After and platform challenges quarter mechanisms is of of Ed. efficacy, cell first controls candidates product immunotherapy down and commitment remain action differentiated with deliver a profile renewed community proprietary based to including some with setting. multiple a patients, permits we We product incorporate energy, uniquely highly shelf novel broad to the create cellular the maximize iPSC synthetic confident function, maintain XXXX, safety bring staring suited in to iPSC-derived have patients accessibility disorders. that of that emerged to that off clinical in
with made this remains BCMA-targeted cell off by antibody myeloma. and off the CDXX-targeted That multiple landscape is is course throughout and combination which points community is administered across the monoclonal few therapeutic the used settings to enabling patients antibodies myeloma NK offer uniquely an The for differentiated of FTXXX myeloma widely antigen cytotoxicity, proposition believe dependent therapy, reach FTXXX lines into in first fragmented the designed regimens combination strides the our CDXX-targeted program cells, in vast combination receiving and cellular inflection for programs. multiple targeting treatment with to of shelf therapy our We year, patient be months treatment. we based of therapy. multi the positioning of highly have community monoclonal studies. company of antibody shelf may attractive multiple lines across reach great based regimens key During the CAR of in majority of
have treatment cohort the reported million] and favorable clinical dose data combination at the Phase profile a single interim which clinical [XXX previously safety (ph) showed We cells, activity. I of first from
indicated data create cohort FTXXX constitution may activated Additionally, newly immune that a extend from persistence. translational rapid suggesting functional positive the through and and of first month of cells CDXX selective the host profile combination depletion therapy, favorable to
our of FTXXX patients CDXX-targeted enroll monoclonal combination in stage escalation in therapy. dose As prioritized continue Phase study, we we of the antibody to enrollment have with I
X assess clearance, dose cells are treatment XXX upon And enrolling We open cohort cohort to at dose. a a two billion cells dose per and at treatment million three dose. currently per expect we
lymphoma In patients immediate are autologous settings. of [indiscernible] with the cell vast CAR off that reduce remarkable numerous where logistical whether controls conditioning or program or to receive lymphoma, of the CAR NK functional disease therapy commonly intense therapies cell designed CDXX-targeted intervention, administered aggressiveness community chemotherapy T-cell CAR to inability to that persistence to efficacy, function, increase cell synthetic requiring shelf our for and incorporates eliminate has do based is shown the of to not barriers, NK combine of majority for five due administer patients. the B-cell T-cell FTXXX standard potency, area care B-cell therapy in autologous enhance need reasons, novel
first cells, designed which to our induce cell and alloimmune to FTXXX post ADR Notably product target the or incorporate candidate receptor, activation. proprietary NK immune is expressing technology, XXBB defense is
standard have diagnosed ADR of data potent for Including combined to widely the we in of demonstrating believe is with patients presence activity significant armed FTXXX allo-reactive opportunity newly presented previously disease. exhibit used and seamlessly T-cells NK treatment that settings. be community CAR based immunotherapies preclinical care [indiscernible] antitumor We with iPSC-derived a for there cells
new am steamer schedule to and that positioned submitted have at of three pleased in drug of the including we investigation patient recently believe clinical We treatment schedule. announce administration with investigational antibody patients. the FDA designed a to well a proposed The is we to assess to therapy, FTXXX. combination CD application dose dose targeted I clinical enrollment dose monoclonal In an therapeutically are to relevant without initiate chemotherapy half intensive second of and XXXX. conditioning to initiate
FTXXX. Phase We to into our of also continue landmark X include patients study
candidate Our B-cell locus, track key novel which including shelf intended CAR CDXX for cell the FTXXX targeted incorporates prevent and expression, XXX balance, into features, CAR off iPSC-derived of T-cell uniform graft construct kind the several promote exhaustion, the product versus of a host CAR is to first integration activation malignancies. disease.
plan I who expansion interim CAR data, Phase The We of we including dose at to XXX cells CDXX in are demonstrated in favorable safety a failed targeted enrolling currently in T-cell patients is treatment patients, cohort lymphoma. not Phase single in autologous showed the therapy. initiate previously middle clinical for XXXX. have eligible a responses a and who in B-cell profile dose have cohort heavily previously million patients pretreated I And which reported study
enable immune excited treatment that patients therapy disease T-cell CAR T-cell dose lymphocytic single to due limited to also our iPSC-derived dysfunction the We to where cell iPSC-derived tumors. tumors to to our solutions heterogeneity. effective is at address safe for expand believe product the continue need chronic multiplex effective of leukemia, may CAR remains cohort specifically a million We're platform product overcome of solid the immunosuppressive and tumor which platform trafficking, the treatment challenges and CAR enroll to patient's within We solid these designed tumor T-cell in utilization to inherent a cells therapeutic incurable XXX autologous and and microenvironment, is in system.
candidate Under T-cell by supporting including candidate to incorporates enhance to eliciting controls immunosuppressive iPSC-derived or we currently expressing promoting in function, our HERX novel IND The ONO, synthetic growth seven without engineer product cell designed exhaustion. solid product the signals X enabling epidural tumors. with human FTXXX/ONO-XXXX. multiplex site, for conducting redirected are collaboration CAR factor trafficking T-cell tumor A activation cell effector targeting activities microenvironment, the tumor and
engaged developing on of an our We the in track currently to remain FTXXX/ONO-XXXX for are XXXX. we application IND second with the strategy are jointly addition, ONO In and for submit team clinical FTXXX/ONO-XXXX. development clinical half
and Finally, in expressed patients solutions cell system a I'm life. improve the that for excited of therapeutic engaged investigators key patients’ utilizing autoimmune effectively have meaningfully of who have for we multiple there shelf off is the leaders significant where to severe and opinion can report therapy reset that treatment interest immune seen disorders, need quality
models, combination assessing as therapies, currently autoimmune target and CDXX T-cell the disease antibodies with we pathogenic off need to potential FTXXX of durable to the immunosuppressive key durably as as proposition shelf selectively We from for target monotherapy harvest compelling. preclinical manufacture. cells deplete potential T-cells. of are pathogenic well deplete targeted off believe in and cells taper to of cell the to B-cells, the and CDXX therapy the B-cells In autologous and avoided selectively monoclonal therapy FTXXX plasma a prior reactive therapies value the Unlike shelf for an CAR auto is in the the and patient's cell
autoimmune shelf cell timely the intervention, diseases potential by to marked has a an advantage. many which the disease severe as demand on therapy flares, moderate with significant are off require to treat therapeutic Additionally,
plans and to working product generate autoimmunity currently we further development. look our forward platform off the first sharing toward iPSC are in and advance We And additional extend shelf development candidate product our data to preclinical we as clinical our strategy into XXXX.
have would allowed multiple for and emerge sharp creation to strong whose and clinical over pathways I this like period through months. and a transition us employees with Before patience a sincerely we perseverance next our thank close, the foundation, focus to value XX
open up call questions. like I the any would to to now
